In early Monday trading, shares of Amgen (AMGN) rose 0.9% after the company reported results from the VESALIUS-CV study. The data showed that its drug Repatha® (evolocumab) reduced the first major cardiovascular event by 25% and first myocardial infarction by 36% in high-risk patients with no prior events. These findings support broader application of PCSK9 inhibitors.